Heat Biologics (HTBX) is still a solid buy
Heat Biologics (HTBX) currently trades at $0.47 and has fallen by 10% today. Heat joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts. The company is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article. The high forecast for Heat Biologics is $5.00 and the low is $2.00. Notably, the company’s market cap is $36.62 million with a 52 week high of $1.27 and a 52 week low of $0.20. HTBX went down $0.05 from the previous closing price of $0.52. HTBX has changed in price by -0.75 per share in the last 12 months.